1301P Sequential therapy of metastatic pancreatic ductal adenocarcinoma (PDAC) after failure of gemcitabine plus nab-paclitaxel with either 5-FU/folinic acid (5FU/LV) plus irinotecan (FOLFIRI) followed by 5FU/LV plus oxaliplatin (OFF) or the reverse sequence: The PANTHEON trial (AIO PAK 0116)
Saved in:
| Title: | 1301P Sequential therapy of metastatic pancreatic ductal adenocarcinoma (PDAC) after failure of gemcitabine plus nab-paclitaxel with either 5-FU/folinic acid (5FU/LV) plus irinotecan (FOLFIRI) followed by 5FU/LV plus oxaliplatin (OFF) or the reverse sequence: The PANTHEON trial (AIO PAK 0116) |
|---|---|
| Authors: | Modest, D.P.1 (AUTHOR), Heinemann, V.2 (AUTHOR), Schütt, P.3 (AUTHOR), Angermeier, S.4 (AUTHOR), Haberkorn, M.5 (AUTHOR), Waidmann, O.6 (AUTHOR), Graeven, U.7 (AUTHOR), Wille, K.8 (AUTHOR), Kunzmann, V.9 (AUTHOR), Henze, L.10 (AUTHOR), Constantin, C.11 (AUTHOR), De Wit, M.12 (AUTHOR), Denzlinger, C.13 (AUTHOR), Kurreck, A.1 (AUTHOR), Alig, A.H.S.1 (AUTHOR), Stahler, A.1 (AUTHOR), Pelzer, U.1 (AUTHOR), Stintzing, S.1 (AUTHOR), Oettle, H.14 (AUTHOR) |
| Source: | Annals of Oncology. 2022 Supplement 7, Vol. 33, pS1139-S1139. 1p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
